gevokizumab (VPM087) / Xoma, Novartis 
Welcome,         Profile    Billing    Logout  

2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
gevokizumab (VPM087) / Novartis
NCT02366260: An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum

Recruiting
3
5
US
Gevokizumab, Placebo
MedDerm Associates, XOMA (US) LLC
Pyoderma Gangrenosum
10/16
 
NCT03798626: Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers

Active, not recruiting
1
167
Europe, Canada, Japan, US, RoW
Gevokizumab, VPM087, Bevacizumab, Modified FOLFOX6, oxaliplatin, leucovorin, 5-fluorouracil, FOLFIRI, irinotecan, leucovorin, 5-fluorouracil, Ramucirumab, Paclitaxel, Cabozantinib
Novartis Pharmaceuticals
Colorectal Cancer, Gastroesophageal Cancer, Renal Cell Carcinoma
03/23
12/24

Download Options